JACI — Vol 158, Issue 3 (pp. 629–926)
Inflammaging: older adults show 1–5× higher IL-6, TNF, TNFR1 than younger adults (mild-flu-level).
This is driven by CD8+ T-cell GZMK production, CHIP-mutant HSCs with myeloid bias, and senescent-cell secretomes.
The PRACTALL 2025 AI consensus notes 1 in 6 adults now get health information from AI (nearly 1 in 4 under 30), with ambient listening and LLM summaries as the main near-term tools.
JACI: In Practice — Vol 14, Issue 9 (pp. 1941–2178)
The aging in asthma in older adults: immunosenescence → neutrophilic/type-2-low, less ICS-responsive, cognitive impairment/depression bidirectionally worsening asthma.
Secondary immunodeficiency: vaccinate COVID/flu/RSV/zoster/pneumococcus.
The acupressure review notes auricular acupressure evidence is very low certainty for food allergy/asthma, with possible rhinitis benefit.
Antihistamines & dementia (n>100k matched): no dementia signal for any antihistamine vs controls; intranasal steroids slightly protective (P=.007).
GLP-1RA in asthma: consistently fewer exacerbations/utilization in obesity/T2D, partly independent of BMI.
FARE registry (n=2,601): top triggers sunflower/mustard/flaxseed, garlic/black pepper/cinnamon.
Annals of Allergy — September 2026, Vol 137, Issue 3 (pp. 269–408).
Shared decision-making has a striking figure — patients engaged in SDM were up to 80% less likely to contact a lawyer, and SDM adds only ~7% to encounter length.
The AD precision-medicine review maps the current biologic/small-molecule landscape:
- nemolizumab with itch improvement by week 1 for itch-dominant disease
- upadacitinib works for EASI/IGA/pruritus but has a boxed warning
The biomarker-guided asthma review makes a strong case for the "fast and slow lane" model, FeNO ≥40 ppb is 90% specific for asthma when spirometry is nondiagnostic, 80–90% of ICS benefit comes at low–medium doses while higher doses quadruple serious risks.